Back to top
more

SiBone (SIBN)

(Delayed Data from NSDQ)

$13.60 USD

13.60
384,489

-0.02 (-0.15%)

Updated Oct 2, 2024 04:00 PM ET

After-Market: $13.61 +0.01 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 20% (50 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

BioSig (BSGM) Grows in Arrhythmia Care With Subscription Model

BioSig's (BSGM) subscription model for PURE EP provides electrophysiologists and cardiology departments with flexibility.

Thermo Fisher's (TMO) EXTENT Solution Makes Commercial Launch

Thermo Fisher (TMO) announces the commercial launch of the EXTENT Solution with IVDR certification.

Here's Why You Should Retain Tandem Diabetes (TNDM) Now

Investors continue to be optimistic about Tandem Diabetes (TNDM) due to the t:slim X2 insulin pump and new product innovations.

Boston Scientific (BSX) Expands Globally Amid FX Concerns

Boston Scientific's (BSX) Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of GI and pulmonary treatment options.

CVS Health's (CVS) Cordavis to Focus on Biosimilar Products

CVS Health's (CVS) wholly owned subsidiary, Cordavis, is set to bring high-quality biosimilar products to the market.

NanoString (NSTG) Advances in Xenotransplantation With New Study

NanoString's (NSTG) nCounter Analysis System facilitates bulk tissue transcriptome profiling, revealing the intricacies of the immune response through the nCounter Human Organ Transplant Panel.

Myriad Genetics (MYGN) Teams Up to Assess Breast Cancer Risk

Myriad Genetics (MYGN) announces collaboration with Onsite Women's Health to develop a breast cancer risk assessment program.

Align (ALGN) Rides on Growing Invisalign Sales, New Alliances

Align Technology (ALGN) is expanding its sales and marketing by reaching new countries and regions.

Here's Why Investors Should Retain ResMed (RMD) Stock for Now

Investors continue to be optimistic about ResMed (RMD), backed by the continued demand for digital health solutions.

Teleflex (TFX) Upgrades the Arrow ErgoPack Complete System

Teleflex's (TFX) expanded Arrow ErgoPack Complete Kit now includes Hemodialysis and Large Bore catheters.

Edwards Lifesciences (EW) Rides on TAVR Amid Rise in Costs

Edwards Lifesciences' (EW) Surgical Structural Heart business growth is driven by increased penetration of its premium RESILIA products across all regions.

Illumina (ILMN) Expands Presence in India With New Facility

Illumina (ILMN) boosts genomic capabilities in India with a new state-of-the-art Solutions Center.

3 Reasons to Retain Intuitive Surgical (ISRG) in Your Portfolio

Intuitive Surgical (ISRG) continues to raise optimism among investors, owing to its strength in robotics.

Quest Diagnostics (DGX) Base Volume Aids Amid Low COVID Tests

Quest Diagnostics (DGX) continues to witness growth momentum in the cardiometabolic, endocrinology, infectious disease and carrier and prenatal genetic screening services.

Thermo Fisher (TMO) Business Hurt by Low COVID Sales, FX Woe

Thermo Fisher (TMO) is witnessing headwinds in the government and academic end markets.

Bruker (BRKR) Set to Acquire PhenomeX in an All-Cash Deal

Bruker (BRKR) initiates its entry into since-cell biology research solutions with the acquisition of PhenomeX.

Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now

Investors continue to be optimistic about IDEXX (IDXX) due to the CAG business and the company's execution of its growth strategy.

Myriad Genetics (MYGN) Adds ARR to Prolaris Biomarker Test

Myriad Genetics (MYGN) announces the integration of ARR into the Prolaris prostate cancer prognostic test.

Syneos Health (SYNH) to Go Private, Reports Q2 Performance

Syneos Health (SYNH) announces shareholders' approval for the impending merger and releases second-quarter 2023 financial results.

Will Humana (HUM) Q2 Earnings Beat on Strong Pharmacy Business?

Humana's (HUM) second-quarter results are likely to reflect rising premiums and investment income.

Charles River (CRL) to Report Q2 Earnings: What's in Store?

Continued global demand for research models and associated services' strong DSA segment performance is likely to have driven Charles River's (CRL) Q2 revenues.

Can Conifer Weakness Affect Tenet Healthcare's (THC) Q2 Earnings?

Tenet Healthcare's (THC) second-quarter results are likely to reflect higher Ambulatory Care operating revenues and supply costs.

CVRx (CVRX) Reports Q2 Loss, Tops Revenue Estimates

CVRx (CVRX) delivered earnings and revenue surprises of 1.75% and 10.94%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Will Higher Costs Affect HCA Healthcare's (HCA) Q2 Earnings?

HCA Healthcare's (HCA) second-quarter results are likely to reflect increased patient volumes, occupancy rate and cost of supplies.

InMode (INMD) to Post Q2 Earnings: What's in the Cards?

InMode (INMD) is expected to report strong Q2 consumable and service revenues, banking on strong performances of seven patented technologies across 10 product families.